Pulmonary Large-Cell Neuroendocrine Carcinoma: Molecular Heterogeneity, Current Treatment and the Emerging Precision-Oncology Paradigm
Cancers · 07.11.2026 · 18 (21) · 3585
DOI: 10.3390/cancers18213585 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 07.11.2026. Verfasst von Tai-Huang Lee und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical Universit…. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Pulmonary large-cell neuroendocrine carcinoma (LCNEC) is a rare, aggressive malignancy with substantial biological heterogeneity. Genomic studies identify SCLC-like and NSCLC-like spectra, but genomic categories overlap incompletely with transcriptional states. Morphology remains essential: neither neuroendocrine marker positivity nor RB1 status alone distinguishes LCNEC from small-cell lung cancer (SCLC). This narrative review integrates diagnostic limitations, stage-based management, and the clinical implications of profiling. Surgery with systematic nodal assessment is central for resectable disease; postoperative platinum chemotherapy has greater support than perioperative immunotherapy. In advanced disease, platinum-etoposide is a commonly used reference regimen. Retrospective associations involving platinum-gemcitabine or platinum-taxanes in RB1-wild-type tumors remain hypothesis-generating and should not be extended to pemetrexed. LANCE, a durvalumab phase II trial, and preliminary NEJ044 findings provide prospective chemo-immunotherapy observations, although randomized LCNEC-specific evidence remains absent. No standard second-line regimen is established. Rare actionable drivers may support matched treatment, whereas DLL3-directed approaches and FGL1/SPINK1-associated strategies require clinical validation. We propose an evidence-qualified framework separating stage-based care, individualized molecular considerations, and clinical-trial strategies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 80708, Taiwan.
- Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung Gangshan Hospital, Kaohsiung Medical University, Kaohsiung 80708, Taiwan.
- Department of Internal Medicine, Kaohsiung Municipal Siaogang Hospital, Kaohsiung 80708, Taiwan.
- Cancer Center, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 80708, Taiwan.
- School of Post-Baccalaureate Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 80708, Taiwan.
ORCID-Profile: Cheng-Hao Chuang, Chih-Jen Yang
Zitieren
APA
Lee, T. H., Ma, J. Y., Hung, H. Y., Kuo, C. Y., Chen, C. L., Tsai, P. C., Chuang, C. H., & Yang, C. J. (2026). Pulmonary Large-Cell Neuroendocrine Carcinoma: Molecular Heterogeneity, Current Treatment and the Emerging Precision-Oncology Paradigm. Cancers, 18(21), 3585. https://doi.org/10.3390/cancers18213585
Vancouver
Lee TH, Ma JY, Hung HY, Kuo CY, Chen CL, Tsai PC, et al. Pulmonary Large-Cell Neuroendocrine Carcinoma: Molecular Heterogeneity, Current Treatment and the Emerging Precision-Oncology Paradigm. Cancers. 2026;18(21):3585. doi:10.3390/cancers18213585
BibTeX
@article{Lee2026,
author = {Lee, Tai-Huang and Ma, Juei-Yang and Hung, Huei-Yang and Kuo, Chia-Yu and Chen, Chin-Ling and Tsai, Pei-Chi and Chuang, Cheng-Hao and Yang, Chih-Jen},
title = {Pulmonary Large-Cell Neuroendocrine Carcinoma: Molecular Heterogeneity, Current Treatment and the Emerging Precision-Oncology Paradigm},
journal = {Cancers},
year = {2026},
volume = {18},
number = {21},
pages = {3585},
doi = {10.3390/cancers18213585}
}
EUVIMED